$PNBK

Patriot Bank’s Formal Agreement With the OCC Has Been Terminated

Patriot Bank, a wholly owned subsidiary of Patriot National Bancorp (NASDAQ: PNBK), said its OCC Formal Agreement dated Jan. 14, 2025 was terminated effective June 30, 2026, per an OCC order. Patriot Bank expects reduced regulatory costs and fees. Patriot Bank reported $1.3B in total assets.

Original reporting
Published Jul 1, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Patriot Bank’s Formal Agreement With the OCC Has Been Terminated — source image
Decision brief

The 30-second read

$PNBKBullishMed
01

Why it matters

OCC’s order states continued existence of the Formal Agreement is not required because safety/soundness and compliance do not require it. Management expects immediate shareholder benefits via reduced regulatory costs and fees.

02

Market read

Regulatory milestone removes a Formal Agreement, which can reduce compliance burden and improve investor perception of risk and earnings stability for the holding company.

03

What to watch

The release doesn’t quantify cost savings, timing of expense normalization, or whether any other restrictions remain—traders should watch for subsequent filings (e.g., 10-Q/8-K) for financial impact details.

Relevance 7/10Novelty 6/10Timing: effective June 30, 2026; announced July 1, 2026 (pre/early-session news)

Background

Patriot Bank had an OCC Formal Agreement dated January 14, 2025; such agreements typically reflect heightened supervisory requirements around safety/soundness and compliance.

Company-level read

Ticker impact

$PNBKBullishMedium confidence
Context

Patriot National Bancorp’s subsidiary Patriot Bank said its OCC Formal Agreement was terminated effective June 30, 2026, citing reduced regulatory costs.

Expected impact

Near-term upside bias as investors price in reduced regulatory costs/fees and improved regulatory status; magnitude likely modest given the event is at the subsidiary level.

Evidence & confidence

The article provides a clear regulatory milestone (termination effective June 30) and management’s stated shareholder benefit (reduced regulatory costs/fees), but it lacks quantified financial impact or guidance changes.

Market effects

Adds a data point on how OCC Formal Agreements can be lifted, potentially improving sentiment toward similarly situated regional/private banks under heightened supervision.

Limited—specific to a single bank holding company; no broader regional banking stress signal mentioned.

Low—US regulatory action with no cross-border transaction or systemic linkage described.

Counterpoint

Reduced regulatory costs may be partially offset by ongoing supervisory expectations or remediation expenses not eliminated by termination; investors could overestimate near-term earnings benefit.

Key entities

  • Patriot Bank, N.A.

    Wholly owned subsidiary of Patriot National Bancorp; OCC Formal Agreement terminated effective June 30, 2026.

  • Office of the Comptroller of the Currency (OCC)

    Issued the June 30, 2026 order terminating the Formal Agreement.

  • Patriot National Bancorp, Inc. (NASDAQ: PNBK)

    Parent company; subject of the news via its subsidiary’s regulatory milestone.

  • Steven Sugarman

    President and CEO of Patriot Bank; stated termination will reduce regulatory costs/fees and benefit shareholders.

Related articles

$AAPLHighAI 9/10

Apple Owes $5.7 Billion for Infringement of Haptics Patents (1)

A federal jury ruled that Apple must pay $5.7 billion for infringing Taction Technology's haptics patents in iPhones and Apple Watches. The jury found no willful infringement. Apple plans to appeal, stating the Taptic Engine differs from Taction's technology. Taction was financed by Gronostaj and Kenosha, linked to Burford Capital.

$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

$DASHMed

DoorDash (DASH) Settlement Puts Its Undervalued Narrative To The Test

DoorDash (DASH) agreed to a $131.5M settlement with NYC, leading to a 3% stock drop. The stock is down 18.4% in 1 month and 12% YTD, but up 143% over 3 years. Analysts debate its valuation, with some calling it undervalued at $193.36 (vs. fair value of $254) and others noting a high P/E of 99.6x. Growth and expansion plans contrast with labor and regulatory risks.

$ABBVMed

AbbVie (ABBV) Wins A New Lymphoma Nod, Is The Stock Still Cheap?

AbbVie (ABBV) received approval from Health Canada for its drug EPKINLY in combination therapy for follicular lymphoma. The company's shares have risen 15.3% year-to-date and 23.5% over one year. Analysts debate its valuation, with some seeing it as undervalued at $264.34 and others noting a high P/E ratio of 74.5x compared to peers.